Research in antibiotic therapy and antifungal

This research unit in antibiotic therapy includes biochemists, bacteriologists and molecular biologists capable of achieving in vitro and in vivo research. This unit would work in close contact with the production units of proteins, of screening, of protéomique and of medicinal chemistry, as described in more detail.

 

 Next

 

Research in the fields of orphaned or neglected illnesses

 

In the form of close collaborations with academic research, and inside a mixed structure "Nereis / public institutions", it is desirable that such an entity does see the light of day. The expertises of certain technological platforms could invest in this type of research (combinative chemistry, HTS…) Next
 

Research in the heads of series

The role of this entity is the discovery of new therapeutic targets, the identification of heads of series and mechanisms of possible actions as well as the rapid optimisation of these heads of series in innovating medicines. This unit must work in close collaboration and in continuity with, on the one hand research units, and on the other hand all the pre-clinic development units. Its main strengths are in medicinal chemistry, the chemical development, the production of proteins and the crystallography, the synthesis and the analysis of natural products as well as the HTS.

 

The different laboratories comprising this unit would in addition be able to work, within the context of specific contracts, for external enterprises. It divides into:

  		Next

Chemical medicine unit

 

  		Objective : research of hits, molecules representative of a chemical series and whose activity is in accordance with the TPP (target product profile), then (after generally one year) of leads, molecules of moderate activity, but still improvable, in order to obtain (generally after 16-18 months) an EDC, susceptible to enter in the pre clinic phases of research. Next

Automated synthesis unit

 Able to supply the HTS : this participates in the discovery of hits. Via the knowledge of the receptors, of homology of structure, of mechanisms of action or of target proteins, its good working permits the yearly synthesis of several thousands of targeted molecules. Next

Structural analysis unit

  

Objective : to evaluate the conformity between the structure of the "theoretical" molecule and that synthesised de facto by the chemists. Heavy investments (RMN, mass spectro) have been made recently in this unit and constitute one of the major strengths of the entity.

 

 Next

Molecular modelisation and chemo-computing unit

Indispensable for modelising and predicting the behaviour of the molecules facing their active site

 Next
Chemical development unit Assigned to supply the basic " scafolds " allowing the medicinal chemistry to do the variations around a similar skeleton, to supply to the services involved metabolites and comparators, to work on new ways of synthesis permitting the re-preparation of sufficient quantities (upto 250 g) of molecules entering pre-clinic

Next
Biotechnology unit  

Composed of the service of expression of the genes and of the production of proteins. Its activity consists in the production, the purification and the analysis of the proteins obtained by culture of animal cells or fermentation of micro oragnisms. The proteins obtained are used as targets in the HTS and anti-infectious units as well as for crystallography research. One of its major assets is its know-how in preparative chromatography ranging from the milligram to several grams of proteins

 

 Next
Central functions This entity regroups the HTS, more particularly specialized in Profiling (specific targeted sifting), biophysics and bio-structural analysis and bio-statistics Next